ORGS

Orgenesis Inc. [ORGS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ORGS Stock Summary

Top 10 Correlated ETFs

ORGS

Top 10 Correlated Stocks

ORGS

In the News

ORGS Financial details

Company Rating
-
Market Cap
16.84M
Income
2.99M
Revenue
27.75M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
167
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
3.73
Forward P/E
-
PEG
-0.34
P/S
0.44
P/B
0.9
P/C
-
P/FCF
-0.37
Quick Ratio
0.56
Current Ratio
0.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.07
EPS next Y
-
EPS next Q
-
EPS this Y
-35.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-18.92%
Revenue last 5Y
14.07%
Revenue Q/Q
-98.42%
EPS Q/Q
-386.67%
-
-
-
-
SMA20
-16.49%
SMA50
67.61%
SMA100
105.17%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
13%
ROC
-0.27%
Gross Margin
78%
Oper. Margin
-30%
Profit Margin
11%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.25-1.5
52W High
-
52W Low
-
RSI
45.69
Rel Volume
0.01
Avg Volume
251.16K
Volume
3.3K
Perf Week
3.65%
Perf Month
-27.94%
Perf Quarter
89.17%
Perf Half Y
84.55%
-
-
-
-
Beta
1.098
-
-
Volatility
0.1%, 0.37%
Prev Close
-2.16%
Price
2.27
Change
3.18%

Something similar

Top by Market Cap
MSF.DE
BRYN.DE
FB2A.DE
APC.DE
3V64.DE
Top Correlated ETFs
UYLD
Top Correlated Stocks
002686.SZ
TOBAF
AYRO
CAAS
600423.SS
Similar Market Cap
FGI
WSP.L
CCFC
0ENN.L
0660.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 251.16K
  • Market Capitalization 16.84M
  • Employee 167
  • CEO Ms. Vered Caplan M.Sc.
  • Headquarters Germantown,MD,US
  • IPO Date 2012-03-13
  • Website https://www.orgenesis.com

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.